Inverse correlation between natural killer cell and treatment with enzalutamide

The new androgen-receptor-targeted treatment enzalutamide has been approved for castration-resistant and sensitive prostate cancer with/without metastasis. In this study, Clinical Oncologist Ahmed Zedan investigated natural killer cell activity in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.